Axial Spondyloarthritis (axSpA) Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Are the Primary Drivers Supporting the Market Growth of theAxial Spondyloarthritis (axSpA) Market?
The escalating occurrence of spondyloarthritis is projected to spur the progression of the axial spondyloarthritis (axSpa) market. Axial spondyloarthritis affects the axial skeleton, notably the spine and sacroiliac joints, and is a long-term illness. The mounting instances of axial spondyloarthritis (axSpA) are linked to the aging populace and spinal damages stemming from mild mishaps or other incidents. Various remedies are administered to manage pain, control inflammation, and ameliorate the quality of life of those suffering from axSpA. For instance, the Musculoskeletal Health Report 2023 by Versus Arthritis, a UK-based charity for the welfare of arthritis sufferers, stated that by 2022 about 60,000 people had been diagnosed with axial spondyloarthritis and each year, approximately 2,200 adults are newly diagnosed with this condition. Hence, the growing presence of axial spondyloarthritis (axSpa) is stimulating the expansion of the axial spondyloarthritis (axSpa) market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
#How Will the CAGR of the Axial Spondyloarthritis (axSpA) Market Influence Its Overall Growth by 2034?
The market size of axial spondyloarthritis (axspa) has seen substantial growth recently. From 2024 to 2025, there is an expected increase of $6.08 billion to $6.58 billion with a compound annual growth rate (CAGR) of 8.3%. This past growth has been influenced by factors like enhancements in diagnostic standards, progression in biological treatments, heightened awareness of the disease, advancements in genetic research, and progress in clinical trials.
The market for axial spondyloarthritis (axspa) is anticipated to experience robust growth in the forthcoming years, projecting a rise to $9.05 billion by 2029 with a compound annual growth rate (CAGR) of 8.3%. This anticipated expansion during the forecast period is largely due to developments in identifying biomarkers, customised therapies, integration of digital health, an array of treatment options, and backing from healthcare policies. The forecast period is also marked by significant trends such as strategies for early intervention, a focus on patient-centric care, telemedicine and remote consultations, exploration into disease mechanisms, and collaborative decision-making.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12590
What Are the Latest Innovations Influencing theAxial Spondyloarthritis (axSpA) Market?
Driving product innovations is currently a key trend in the axial spondyloarthritis (axSpA) market. Many dominant companies in the axSpA market are focusing on the development of new drugs to maintain their market prominence. Notably, in June 2023, UCB SA, a pharmaceutical company based in Belgium, attained approval from the New European Commission for the marketing of BIMZELX (bimekizumab). Intended for adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) showing objective inflammation signs like high C-reactive protein, the drug has now won its first global marketing licenses for axial spondyloarthritis courtesy of these EU authorizations.
Who Are the Major Industry Players Accelerating Growth in theAxial Spondyloarthritis (axSpA) Market?
Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
Which Primary Segments of the Axial Spondyloarthritis (axSpA) Market Are Driving Growth and Industry Transformations?
The axial spondyloarthritis (axSpA) market covered in this report is segmented –
1) By Types: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
Subsegments:
1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS
2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA, Asymptomatic nr-axSpA
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theAxial Spondyloarthritis (axSpA) Market?# Market?
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Axial Spondyloarthritis (axSpA) Maret 2025, By The Business Research Company:
Arthritis Monoclonal Antibodies Global Market Report 2024
Cervical Spondylosis Treatment Global Market Report 2024
TNF Alpha Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
